Search

Now showing items 1-9 of 9

Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)

Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...

Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection

Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)

Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ...

Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

Kabacam, G.; Dalekos, G. N.; Cakaloglu, Y.; Zachou, K.; Bock, T.; Erhardt, A.; Zeuzem, S.; Tabak, F.; Yalcin, K.; Bozdayi, A. M.; Dienes, H. P.; Bozkaya, H.; Manns, M.; Wedemeyer, H.; Yurdaydin, C. (2012)

Background/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks ...

Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)

Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ...

Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?

Onder, F. O.; Erhardt, A.; Idilman, R.; Keskin, O.; Dalekos, G. N.; Yalcin, K.; Manns, M. P.; Wedemeyer, H.; Yurdaydin, C. (2012)

EFFICACY OF PEGYLATED INTERFERON-BASED TREATMENT IN PATIENTS WITH CIRRHOSIS DUE TO CHRONIC DELTA HEPATITIS: COMPARISON WITH NON-CIRRHOTIC PATIENTS

Yurdaydin, C.; Kobacam, G.; Cakaloglu, Y.; Erhardt, A.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Dalekos, G. N.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2009)

Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the HEP-NET/International HDV Intervention Trial

Zachou, K.; Yurdaydin, C.; Dienes, H. R.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Bock, T.; Schlaphoff, V.; Manns, M. R.; Wedemeyer, H. (2006)

LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA

Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Bock, T.; Idilman, R.; Manns, M. P.; Wedemeyer, H. (2013)

Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment

Mederacke, I.; Yurdaydin, C.; Dalekos, G. N.; Bremer, B.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H.; Hep-Net Int Delta Hepatitis, Study (2012)

Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected ...